ANDA 90039, held by Caplin One Labs. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 90039 (Methotrexate Sodium Preservative Free), held by Caplin One Labs, was first approved by FDA on Mar 31, 2009, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2009 | Original application | Approved | None posted |
| Methotrexate Sodium Preservative FreeEQ 50MG BASE/2ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Discontinued |
| Methotrexate Sodium Preservative FreeEQ 250MG BASE/10ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Discontinued |
| Jan 31, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 31, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 30, 2012 | Supplement 3Labeling | Approved | None posted |
| Mar 31, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters